# US 2024/0391886 A1 · Carbon monoxide prodrugs for the treatment of medical disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0391886 A1
- Document ID: US20240391886A1
- Status: Published application
- Kind: A1
- Application number: 18/770,214
- Filed: 2024-07-11
- Published: 2024-11-28
- Earliest claimed: 2018-10-16
- Assignees: Georgia State University Research Foundation, Inc.
- Applicants: Georgia State University Research Foundation, Inc.
- Inventors: Binghe Wang; Xingyue Ji; Ladie Kimberly De La Cruz; Xiaoxiao Yang
- Web page: https://patentgrep.com/patent/US20240391886A1

## CPC

- A61P 9/02: Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- C07D 291/06: Six-membered rings
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07C 49/16: containing halogen
- C07C 49/417: polycyclic
- C07C 59/205: containing rings
- C07C 59/21: containing halogen
- C07C 59/80: containing rings other than six-membered aromatic rings
- C07C 69/06: of monohydroxylic compounds
- C07C 69/07: of unsaturated alcohols
- C07C 69/36: Oxalic acid esters
- C07C 69/63: of saturated acids
- C07C 69/716: Esters of keto-carboxylic acids {or aldehydo-carboxylic acids}
- C07C 69/757: having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, [IMAGE cpc-sch-C07C-0958.gif] groups,[IMAGE cpc-sch-C07C-0959.gif] groups, or[IMAGE cpc-sch-C07C-0960.gif] in the acid moiety
- C07C 311/19: to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C 311/51: Y being a hydrogen or a carbon atom
- C07D 207/36: Oxygen or sulfur atoms
- C07D 209/48: with oxygen atoms in positions 1 and 3, e.g. phthalimide
- C07D 213/64: attached in position 2 or 6
- C07D 213/74: Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C07D 231/18: One oxygen or sulfur atom
- C07D 231/20: One oxygen atom attached in position 3 or 5
- C07D 239/60: Three or more oxygen or sulfur atoms
- C07D 239/62: Barbituric acids
- C07D 275/04: condensed with carbocyclic rings or ring systems
- C07D 275/06: with hetero atoms directly attached to the ring sulfur atom
- C07D 285/01: Five-membered rings
- C07D 285/04: not condensed with other rings
- C07D 285/125: with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D 285/14: condensed with carbocyclic rings or ring systems
- C07D 307/60: Two oxygen atoms, e.g. succinic anhydride
- C07D 319/06: not condensed with other rings
- C07D 333/32: Oxygen atoms
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 409/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 417/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07C 2601/08: the ring being saturated
- C07C 2601/10: the ring being unsaturated
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

The present invention provides new compounds and compositions thereof that release carbon monoxide for the treatment of medical disorders that are responsive to carbon monoxide, for example, inflammatory, pain, and dermatological disorders.

## Claims

### Claim 1

A compound of Formula I:
or a pharmaceutically acceptable salt thereof;
wherein A is selected from:
R1 is independently selected at each occurrence from halogen, hydroxyl, alkyl, haloalkyl, alkoxy, haloalkoxy, aryl, heteroaryl, thiol, thioalkyl, —(C═O)RS, —O(C═O)RS, cyano, —SO3H, —(P═O)(OH)2, —O(P═O)(OH)2, and nitro;
R1A is independently selected at each occurrence from halogen, hydroxyl, alkyl, haloalkyl, alkoxy, haloalkoxy, aryl, heteroaryl, thiol, —(C═O)RS, —O(C═O)RS, cyano, —SO3H, —(P═O)(OH)2, —O(P═O)(OH)2, and nitro;
R2 and R2′ are independently selected from hydrogen, alkyl, haloalkyl, aryl, and heteroaryl;
R3 is independently selected at each occurrence from halogen, alkyl, haloalkyl, aryl, heteroaryl, and
R4 and R4′ are independently alkyl;
R5 and R5′ are independently selected from hydrogen, halogen, hydroxyl, alkyl, haloalkyl, aryl, and heteroaryl;
R5″ is selected from hydrogen, alkyl, aryl, and heteroaryl;
R6 and R6′ are independently selected from hydrogen, alkyl, haloalkyl, aryl, and heteroaryl;
R7 is independently selected at each occurrence from hydrogen, alkyl, haloalkyl, aryl, and heteroaryl;
R11 is selected from hydrogen, halogen, alkyl, haloalkyl, aryl, and heteroaryl;
R12 is selected from hydrogen, halogen, alkyl, haloalkyl, aryl, and heteroaryl;
R14 is selected from hydrogen, alkyl, aryl, and heteroaryl;
RS is selected from hydrogen, alkyl, haloalkyl, alkoxy, amino, alkylamino, dialkylamino, aryl, and heteroaryl;
X1 is —C(R5)(R5′)—, —N(R5″)—, —O—, or —S—;
m is independently selected from 0, 1, 2, 3, or 4; and
o is selected from 1, 2, 3, or 4.

### Claim 2 (depends on 1)

The compound of claim 1, having a formula selected from:
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

The compound of claim 1, which is selected from:

### Claim 4 (depends on 1)

A method for the treatment of a medical disorder that can be treated with carbon monoxide comprising administering an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, to a subject in need thereof.

### Claim 5 (depends on 4)

The method of claim 4, wherein the compound has a formula selected from:
or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 4)

The method of claim 4, wherein the compound is selected from:

### Claim 7 (depends on 4)

The method of claim 4, wherein the medical disorder is an inflammatory disorder or a pain disorder.

### Claim 8 (depends on 4)

The method of claim 4, wherein the medical disorder is selected from neuropathic pain, inflammatory pain, postoperative pain, osteoarthritis, pain associated with metastatic cancer, trigeminal neuralgia, acute herpetic neuralgia, post-herpetic neuralgia, diabetic neuropathy, causalgia, brachial plexus avulsion, occipital neuralgia, reflex sympathetic dystrophy, fibromyalgia, gout, phantom limb pain, acne vulgaris, atherosclerosis, ischemia reprufusion injury, acute kidney injury, heavy metal poisoning, pancreatitis, and chemotherapy-induced acute kidney injury, and chemotherapy-induced cardiotoxicity.

### Claim 9 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 in a pharmaceutically acceptable carrier.

### Claim 10 (depends on 9)

The pharmaceutical composition of claim 9, wherein the composition is a solid dispersion.

### Claim 11 (depends on 10)

The pharmaceutical composition of claim 10, wherein the composition comprises activated charcoal, polyvinylpyrrolidone, a polyvinylpyrrolidone/vinyl acetate copolymer, or a combination thereof.

### Claim 12 (depends on 1)

A solid dispersion pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier.

### Claim 13

A method for the treatment of a medical disorder that can be treated with carbon monoxide comprising administering an effective amount of a compound of Formula IV:
or a pharmaceutically acceptable salt thereof;
wherein A1 is selected from:
R1 is independently selected at each occurrence from halogen, hydroxyl, alkyl, haloalkyl, alkoxy, haloalkoxy, aryl, heteroaryl, thiol, thioalkyl, —(C═O)RS, —O(C═O)RS, cyano, —SO3H, —(P═O)(OH)2, —O(P═O)(OH)2, and nitro;
R2 and R2′ are independently selected from hydrogen, alkyl, haloalkyl, aryl, and heteroaryl;
R3 is independently selected at each occurrence from halogen, alkyl, haloalkyl, aryl, heteroaryl, and
R5 and R5′ are independently selected from hydrogen, halogen, hydroxyl, alkyl, haloalkyl, aryl, and heteroaryl;
R5″ is selected from hydrogen, alkyl, aryl, and heteroaryl;
R6 and R6′ are independently selected from hydrogen, alkyl, haloalkyl, aryl, and heteroaryl;
R7 is independently selected at each occurrence from hydrogen, alkyl, haloalkyl, aryl, and heteroaryl;
R8 and R8′ are independently selected from alkyl and aryl;
R9 is selected from alkyl, haloalkyl, aryl, and heteroaryl;
R10 and R10′ are independently selected from alkyl, aryl, and heteroaryl;
R11 is selected from hydrogen, halogen, alkyl, haloalkyl, aryl, and heteroaryl;
R13 and R13′ are independently selected from hydrogen, alkyl, haloalkyl, aryl, and heteroaryl;
R15 is independently selected at each occurrence from hydrogen, halogen, alkyl, haloalkyl, aryl, and heteroaryl;
R16 and R16′ are independently selected at each occurrence from alkyl, haloalkyl, aryl, heteroaryl, alkoxy, haloalkoxy, aryloxy, heteroaryloxy, amino, alkylamino, and dialkylamino;
R17 is selected from halogen, haloalkyl, and nitro;
Rm, Rn, Ro, and Rp are independently selected from hydrogen, halogen, hydroxyl, alkyl, haloalkyl, alkoxy, haloalkoxy, aryl, and heteroaryl;
RS is selected from hydrogen, alkyl, haloalkyl, alkoxy, amino, alkylamino, dialkylamino, aryl, and heteroaryl; and
X1 is —C(R5)(R5′)—, —N(R5″)—, —O—, or —S—;
m is independently selected from 0, 1, 2, 3, or 4; and
n is independently selected at each occurrence from 0, 1, 2, 3, 4, and 5.

### Claim 14 (depends on 13)

The method of claim 13, wherein the compound has a formula selected from:
or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 13)

The method of claim 13, wherein the compound is selected from:

### Claim 16 (depends on 13)

The method of claim 13, wherein the medical disorder is an inflammatory disorder or a pain disorder.

### Claim 17 (depends on 13)

The method of claim 13, wherein the medical disorder is selected from neuropathic pain, inflammatory pain, postoperative pain, osteoarthritis, pain associated with metastatic cancer, trigeminal neuralgia, acute herpetic neuralgia, post-herpetic neuralgia, diabetic neuropathy, causalgia, brachial plexus avulsion, occipital neuralgia, reflex sympathetic dystrophy, fibromyalgia, gout, phantom limb pain, acne vulgaris, atherosclerosis, ischemia reprufusion injury, acute kidney injury, heavy metal poisoning, pancreatitis, and chemotherapy-induced acute kidney injury, and chemotherapy-induced cardiotoxicity.
